vimarsana.com
Home
Live Updates
Isa-KRd Elicits MRD-Negative Remissions in Newly Diagnosed,
Isa-KRd Elicits MRD-Negative Remissions in Newly Diagnosed,
Isa-KRd Elicits MRD-Negative Remissions in Newly Diagnosed, High-Risk Myeloma
Treatment with the combination of isatuximab, carfilzomib, lenalidomide, and dexamethasone generated high rates of minimal residual disease negativity in patients with newly diagnosed, high-risk multiple myeloma, irrespective of transplant status.
Related Keywords
Hamburg ,
Germany ,
Dana Farber Cancer Institute ,
Massachusetts ,
United States ,
Eppendorf ,
Nordrhein Westfalen ,
Boston ,
Lisa Leypoldt ,
Department Of Medicine At Harvard Medical School ,
Bristol Myers Squibb ,
University Medical Center Hamburg ,
International Staging Score ,
International Myeloma Society Annual Meeting ,
Myeloma Society Annual Meeting ,
University Medical Center Hamburg Eppendorf ,
Medical Oncology ,
Harvard Medical School ,
Second Revision ,
Isatuximab ,
Carfilzomib ,
Lenalidomide ,
Nd Dexamethasone ,
Patients With Newly Diagnosed ,
High Risk Multiple Myeloma ,
Gmmg Concept Trial ,
Nct03104842 ,
D ,